

200 Park Avenue, 17th Floor, New York, NY 10166  
sirillp.com | P: (212) 532-1091 | F: (646) 417-5967

## VIA E-MAIL AND FEDERAL EXPRESS

September 15, 2021

Dr. Rochelle P. Walensky, Director  
Centers for Disease Control and Prevention  
Roybal Bldg. 21, Rm 12000  
1600 Clifton Road  
Atlanta, GA 30333  
[Aux7@cdc.gov](mailto:Aux7@cdc.gov)

### UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION

#### **SUPPLEMENTAL EXHIBIT TO CITIZEN PETITION FOR THE ISSUANCE OF A RULE REGARDING FREEDOMS FOR THE CONVALESCED FOLLOWING COVID- 19 DISEASE**

This petition for administrative action was submitted on behalf of Informed Consent Action Network<sup>1</sup> (“**Petitioner**”) on July 6, 2021 pursuant to 5 U.S.C. § 553(e) to request that the Director of the Centers for Disease Control and Prevention update the agency’s guidance, recommendations, and rules to provide for the same freedoms for the convalescent as provided for those vaccinated for COVID-19. The petition attached, as Exhibit A, a letter submitted on May 28, 2021 regarding same and, as Exhibit B, the CDC’s June 21, 2021 response.

Petitioner, to date, has not received a response to the petition and respectfully submits the attached list of recent relevant studies regarding the topic at issue in the petition, as Exhibit C. If we do not receive a substantive response to this request within 21 days, we have been directed by Petitioner to file an action in federal court.

Best regards,



Aaron Siri, Esq.  
Elizabeth A. Brehm, Esq.  
Caroline Tucker, Esq.  
Jessica Wallace, Esq.

---

<sup>1</sup> Including, but not limited to, on behalf of its members, including those who work for Petitioner.

## EXHIBIT C

### **SUPPLEMENTAL EXHIBIT TO CITIZEN PETITION FOR THE ISSUANCE OF A RULE REGARDING FREEDOMS FOR THE CONVALESCED FOLLOWING COVID- 19 DISEASE**

1. Xu J, Zhao S, Teng T, et al. Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. *Viruses*. 2020;12(2):244. Published February 22, 2020. doi:10.3390/v12020244 available at <https://pubmed.ncbi.nlm.nih.gov/32098422/>.
2. Van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, Avanzato V, Bushmaker T, Flaxman A, Ulaszewska M, Feldmann F, Allen ER, Sharpe H, Schulz J, Holbrook M, Okumura A, Meade-White K, Pérez-Pérez L, Bissett C, Gilbride C, Williamson BN, Rosenke R, Long D, Ishwarbhai A, Kailath R, Rose L, Morris S, Powers C, Lovaglio J, Hanley PW, Scott D, Saturday G, de Wit E, Gilbert SC, Munster VJ. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. *bioRxiv [Preprint]*. May 13, 2020:2020.05.13.093195. doi: 10.1101/2020.05.13.093195. <https://pubmed.ncbi.nlm.nih.gov/32511340/>.
3. Khan I, Hatiboglu MA. Can COVID-19 induce glioma tumorigenesis through binding cell receptors? *Med Hypotheses*. 2020 Nov;144:110009. doi: 10.1016/j.mehy.2020.110009. Epub 2020 Jun 19. PMID: 32758869; PMCID: PMC7303027; June 19, 2020; <http://dx.doi.org/10.1016/j.mehy.2020.110009>.
4. Singh N, Bharara Singh A. S2 subunit of SARS-nCoV-2 interacts with tumor suppressor protein p53 and BRCA: an in silico study. *Transl Oncol*. 2020;13(10):100814. doi:10.1016/j.tranon.June30,2020.100814; <http://dx.doi.org/10.1016/j.tranon.2020.100814>.
5. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, Lin M, Tan N, Linster M, Chia WN, Chen MI, Wang LF, Ooi EE, Kalimuddin S, Tambyah PA, Low JG, Tan YJ, Bertoletti A. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature*. August 2020;584(7821):457-462. doi: 10.1038/s41586-020-2550-z. Epub 2020 Jul 15. PMID: 32668444 available at <https://pubmed.ncbi.nlm.nih.gov/32668444/>; <https://www.nature.com/articles/s41586-020-2550-z>.
6. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, Mills R, Teng E, Kamruzzaman M, Garcia-Beltran WF, Astudillo M, Yang D, Miller TE, Oliver E, Fischinger S, Atyeo C, Iafrate AJ, Calderwood SB, Lauer SA, Yu J, Li Z, Feldman J, Hauser BM, Caradonna TM, Branda JA, Turbett SE, LaRocque RC, Mellon G, Barouch DH, Schmidt AG, Azman AS, Alter G, Ryan ET, Harris JB, Charles RC. Dynamics and significance of the antibody response to SARS-CoV-2 infection. *medRxiv [Preprint]*. July 20, 2020.07.18.20155374. doi: 10.1101/2020.07.18.20155374. PMID: 32743600; PMCID: PMC7386524. <https://pubmed.ncbi.nlm.nih.gov/32743600/>.

7. Jun Wu, Boyun Liang, Cunrong Chen, Hua Wang, Yaohui Fang, Shu Shen, Xiaoli Yang, Baoju Wang, Liangkai Chen, Qi Chen, Yang Wu, Jia Liu, Xuecheng Yang, Wei Li, Bin Zhu, Wenqing Zhou, Huan Wang, Shumeng Li, Sihong Lu, Di Liu, Huadong Li, Adalbert Krawczyk, Mengji Lu, Dongliang Yang, Fei Deng, Ulf Dittmer, Mirko Trilling, Xin Zheng; SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19; medRxiv 2020.07.21.20159178; doi: <https://doi.org/10.1101/2020.07.21.20159178>; July 21, 2020; <https://www.medrxiv.org/content/10.1101/2020.07.21.20159178v1>.
  
8. McCullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, Wheelan KR, Katz N, Lepor NE, Vijay K, Carter H, Singh B, McCullough SP, Bhambi BK, Palazzuoli A, De Ferrari GM, Milligan GP, Safder T, Tecson KM, Wang DD, McKinnon JE, O'Neill WW, Zervos M, Risch HA. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. *Am J Med.* 2021 Jan;134(1):16-22. doi: 10.1016/j.amjmed.2020.07.003. Epub August 7, 2020. PMID: 32771461; PMCID: PMC7410805 available at <https://pubmed.ncbi.nlm.nih.gov/32771461/>;  
  
McCullough PA, Alexander PE, Armstrong R, Arvinte C, Bain AF, Bartlett RP, Berkowitz RL, Berry AC, Borody TJ, Brewer JH, Brufsky AM, Clarke T, Derwand R, Eck A, Eck J, Eisner RA, Fareed GC, Farella A, Fonseca SNS, Geyer CE Jr, Gonnering RS, Graves KE, Gross KBV, Ariel Israel, Yotam Shenhar, Ilan Green, Eugene Merzon, Avivit Golan-Cohen, Alejandro A Schäffer, Eytan Ruppim, Shlomo Vinker, Eli Magen; Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection; medRxiv August 19, 2020; 21262111; doi: <https://doi.org/10.1101/2021.08.19.21262111>; <https://www.medrxiv.org/content/10.1101/2021.08.19.21262111v1>.
  
9. Zhang, S., Liu, Y., Wang, X. *et al.* SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. *J Hematol Oncol* 13, 120 (September 4, 2020). <https://doi.org/10.1186/s13045-020-00954-7>; <http://dx.doi.org/10.1186/s13045-020-00954-7>.
  
10. Yuichiro J. Suzuki, Sofia I. Nikolaienko, Vyacheslav A. Dibrova, Yulia V. Dibrova, Volodymyr M. Vasylyk, Mykhailo Y. Novikov, Nataliia V. Shults, Sergiy G. Gychka; SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells; bioRxiv 2020.10.12.335083; doi: <https://doi.org/10.1101/2020.10.12.335083>; Now published in *Vascular Pharmacology* doi: 10.1016/j.vph.2020.106823; October 12, 2020; <http://dx.doi.org/10.1016/j.vph.2020.106823>.
  
11. Schwarzkopf S, Krawczyk A, Knop D, Klump H, Heinold A, Heinemann FM, Thümmeler L, Temme C, Breyer M, Witzke O, Dittmer U, Lenz V, Horn PA, Lindemann M. Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG. *Emerg Infect Dis.* January 2021;27(1). doi: 10.3201/2701.203772. Epub October 15, 2020. PMID: 33058753 available at <https://pubmed.ncbi.nlm.nih.gov/33058753/>.

12. Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. *N Engl J Med.* 2020;383(16):1544-1555. doi:10.1056/NEJMoa2024671;October15,2020. <https://www.nejm.org/doi/full/10.1056/NEJMoa2024671>;
13. Alana F Ogata, Adam M Maley, Connie Wu, Tal Gilboa, Maia Norman, Roey Lazarovits, Chih-Ping Mao, Gail Newton, Matthew Chang, Katrina Nguyen, Maliwan Kamkaew, Quan Zhu, Travis E Gibson, Edward T Ryan, Richelle C Charles, Wayne A Marasco, David R Walt, Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease, *Clinical Chemistry*, Volume 66, Issue 12, December 2020, Pages 1562–1572, <https://doi.org/10.1093/clinchem/hvaa213>; <http://dx.doi.org/10.1093/clinchem/hvaa213>.
14. Patra T, Meyer K, Geerling L, Isbell TS, Hoft DF, Brien J, Pinto AK, Ray RB, Ray R. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells. *PLoS Pathog.* December 7, 2020;16(12):e1009128. doi:10.1371/journal.ppat.1009128.PMID:33284859;PMCID: PMC7746263.; <http://dx.doi.org/10.1371/journal.ppat.1009128>.
15. Rhea, E.M., Logsdon, A.F., Hansen, K.M. *et al.* The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice. *Nat Neurosci* 24, 368–378 (2021). December 16, 2020. <https://doi.org/10.1038/s41593-020-00771-8>; <http://dx.doi.org/10.1038/s41593-020-00771-8>.
16. Hazan S, Held KS, Hight HT, Immanuel S, Jacobs MM, Ladapo JA, Lee LH, Littell J, Lozano I, Mangat HS, Marble B, McKinnon JE, Merritt LD, Orient JM, Oskoui R, Pompan DC, Procter BC, Prodromos C, Rajter JC, Rajter JJ, Ram CVS, Rios SS, Risch HA, Robb MJA, Rutherford M, Scholz M, Singleton MM, Tumlin JA, Tyson BM, Urso RG, Victory K, Vliet EL, Wax CM, Wolkoff AG, Wooll V, Zelenko V. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). *Rev Cardiovasc Med.* December 30, 2020;21(4):517-530. doi:10.31083/j.rcm.2020.04.264.PMID:33387997\_available\_at <https://pubmed.ncbi.nlm.nih.gov/33387997/>.
17. Suresh SJ, Suzuki YJ. SARS-CoV-2 Spike Protein and Lung Vascular Cells. *Journal of Respiration.* 2021;1(1):40-48; December 31, 2020; <https://doi.org/10.3390/jor1010004>; <https://www.mdpi.com/2673-527X/1/1/4>.
18. Schulien I, Kemming J, Oberhardt V, Wild K, Seidel LM, Killmer S, Sagar, Daul F, Salvat Lago M, Decker A, Luxenburger H, Binder B, Bettinger D, Sogukpinar O, Rieg S, Panning M, Huzly D, Schwemmle M, Kochs G, Waller CF, Nieters A, Duerschmied D, Emmerich F, Mei HE, Schulz AR, Llewellyn-Lacey S, Price DA, Boettler T, Bengsch B, Thimme R, Hofmann M, Neumann-Haefelin C. Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells. *Nat Med.* January 2021;27(1):78-85. doi: 10.1038/s41591-020-01143-2. Epub PMID: 33184509 available at <https://pubmed.ncbi.nlm.nih.gov/33184509/>.

19. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, Saphire EO, Smith DM, Weiskopf D, Sette A, Crotty S. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*; 5;371(6529):eabf4063. doi: 10.1126/science.abf4063. Epub January 6, 2021. PMID: 33408181; PMCID: PMC7919858. <https://pubmed.ncbi.nlm.nih.gov/33408181/>.
20. Suzuki YJ, Gychka SG. SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. *Vaccines*. 2021; 9(1):36. January 11, 2021; <https://doi.org/10.3390/vaccines9010036>; <http://dx.doi.org/10.3390/vaccines9010036>.
21. Florian Krammer, Komal Srivastava, the PARIS team, Viviana Simon; Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine; January 29, 2021; medRxiv 2021.01.29.21250653; doi: <https://doi.org/10.1101/2021.01.29.21250653>.
22. Alexander G. Mathioudakis, Murad Ghrew, Andrew Ustianowski, Shazaad Ahmad, Ray Borrow, Lida Pieretta Papavasileiou, Dimitrios Petrakis, Nawar Diar Bakerly; Self-reported real-world safety and reactogenicity of COVID-19 vaccines: An international vaccine-recipient survey, February 26, 2021; medRxiv 2021.02.26.21252096; doi:<https://doi.org/10.1101/2021.02.26.21252096>; <https://www.medrxiv.org/content/10.1101/2021.02.26.21252096v1>.
23. Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, Aiano F, Amin-Chowdhury Z, Hallis B, Stapley L, Borrow R, Linley E, Ahmad S, Parker B, Horsley A, Amirthalingam G, Brown K, Ramsay ME, Ladhani S, Moss P. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. *Nat Immunol*. May 2021;22(5):620-626. doi: 10.1038/s41590-021-00902-8. Epub March 5, 2021. PMID: 33674800; PMCID: PMC7610739 available at <https://www.nature.com/articles/s41590-021-00902-8>.
24. Blumenthal KG, Robinson LB, Camargo CA, et al. Acute Allergic Reactions to mRNA COVID-19 Vaccines. *JAMA*. 2021;325(15):1562–1565. doi:10.1001/jama; March 8, 2021.3976; <https://jamanetwork.com/journals/jama/fullarticle/2777417>.
25. Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP, Petrakis D, Bakerly ND. Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. *Life*. March 17, 2021; 11(3):249. <https://doi.org/10.3390/life11030249>; <https://www.mdpi.com/2075-1729/11/3/249>.
26. Development of Syncytialized Placenta, Its Limited Homology to the SARS-CoV-2 Spike Protein and Arguments against Disturbing Narrative in the Context of COVID-19 Vaccination. *Biology (Basel)*. March 19, 2021;10(3):238. doi: 10.3390/biology10030238. PMID: 33808658; PMCID: PMC8003504. <http://dx.doi.org/10.3390/biology10030238>.

27. Carmen Camara, Daniel Lozano-Ojalvo, Eduardo Lopez-Granados, Estela Paz-Artal, Marjorie Pion, Rafael Correa-Rocha, Alberto Ortiz, Marcos Lopez-Hoyos, Marta Erro Iribarren, Jose Portoles, Pilar Portoles, Mayte Perez-Olmeda, Jesus Oteo, Cecilia Berin, Ernesto Guccione, Antonio Bertoletti, Jordi Ochando ; Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals; March 22, 2021; bioRxiv 2021.03.22.436441; doi: <https://doi.org/10.1101/2021.03.22.436441>.
28. Rachael K. Raw, Clive Kelly, Jon Rees, Caroline Wroe, David R. Chadwick; Previous COVID-19 infection but not Long-COVID is associated with increased adverse events following BNT162b2/Pfizer vaccination; April 15, 2021; medRxiv 2021.04.15.21252192; doi: <https://doi.org/10.1101/2021.04.15.21252192>; <https://www.medrxiv.org/content/10.1101/2021.04.15.21252192v1>.
29. Yair Goldberg, Micha Mandel, Yonatan Woodbridge, Ronen Fluss, Ilya Novikov, Rami Yaari, Arnona Ziv, Laurence Freedman, Amit Huppert ; Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel; April 20, 2021; medRxiv 2021.04.20.21255670; doi: <https://doi.org/10.1101/2021.04.20.21255670>; <https://www.medrxiv.org/content/10.1101/2021.04.20.21255670v1>.
30. Ivanova EN, Devlin JC, Buus TB, et al. Discrete immune response signature to SARS-CoV-2, mRNA vaccination versus infection. Preprint. *medRxiv*. 2021;2021.04.20.21255677. Published April 21, 2021. doi:10.1101/2021.04.20.21255677; <https://pubmed.ncbi.nlm.nih.gov/33907755/>.
31. Laith J. Abu-Raddad, et al.; SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy; *The Lancet*; April 27, 2021; [https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(21\)00141-3/fulltext#%20](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00141-3/fulltext#%20).
32. Angeli F, Spanevello A, Reboldi G, Visca D, Verdecchia P. SARS-CoV-2 vaccines: Lights and shadows. *Eur J Intern Med*. 2021;88:1-8. April 29, 2021; doi:10.1016/j.ejim; <http://dx.doi.org/10.1016/j.ejim.2021.04.019>.
33. Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. *Circ Res*. April 30, 2021; 128(9):1323-1326. doi:10.1161/CIRCRESAHA.121.318902; <http://dx.doi.org/10.1161/CIRCRESAHA.121.318902>.
34. Liguozhang, Alexsia Richards, M. Inmaculada Barrasa, Stephen H. Hughes, Richard A. Young, Rudolf Jaenisch; Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues; *Proceedings of the National Academy of Sciences*; May 2021, 118 (21) e2105968118; DOI: 10.1073/pnas.2105968118; <http://dx.doi.org/10.1073/pnas.2105968118>.

35. Claudia Gonzalez, Carla Saade, Antonin Bal, Martine Valette, Kahina Saker, Bruno Lina, Laurence Josset, Mary-Anne Trabaud, Guillaume Thiery, Elisabeth Botelho-Nevers, Stéphane Paul, Paul Verhoeven, Thomas Bourlet, Sylvie Pillet, Florence Morfin, Sophie Trouillet-Assant, Bruno Pozzetto, Live virus neutralisation testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2; May 11, 2021; medRxiv 2021.05.11.21256578; doi:<https://doi.org/10.1101/2021.05.11.21256578>; <https://www.medrxiv.org/content/10.1101/2021.05.11.21256578v1>.
36. Alana F Ogata, Chi-An Cheng, Michaël Desjardins, Yasmeeen Senussi, Amy C Sherman, Megan Powell, Lewis Novack, Salena Von, Xiaofang Li, Lindsey R Baden, David R Walt, Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients, *Clinical Infectious Diseases*, May 20, 2021, ciab465, <https://doi.org/10.1093/cid/ciab465>; <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075>.
37. Idrees D, Kumar V. SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration. *Biochem Biophys Res Commun*. 2021;554:94-98. May 21, 2021; doi:10.1016/j.bbrc.2021.03.100; <http://dx.doi.org/10.1016/j.bbrc.2021.03.100>.
38. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, Hansen L, Haile A, Klebert MK, Pusic I, O'Halloran JA, Presti RM, Ellebedy AH. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Epub May 24, 2021; PMID: 34030176.<https://pubmed.ncbi.nlm.nih.gov/34030176/>;<https://www.nature.com/articles/s41586-021-03647-4>.
39. O Murchu E, Byrne P, Carty PG, De Gascun C, Keogan M, O'Neill M, Harrington P, Ryan M. Quantifying the risk of SARS-CoV-2 reinfection over time. *Rev Med Virol*. May 27, 2021:e2260. doi: 10.1002/rmv.2260. Epub ahead of print. PMID: 34043841; PMCID: PMC8209951.<https://pubmed.ncbi.nlm.nih.gov/34043841/>.
40. Nielsen SS, Vibholm LK, Monrad I, Olesen R, Frattari GS, Pahus MH, Højen JF, Gunst JD, Erikstrup C, Holleufer A, Hartmann R, Østergaard L, Søggaard OS, Schleimann MH, Tolstrup M. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. *EBioMedicine*. June 2021;68:103410. doi: 10.1016/j.ebiom.2021.103410. Epub June 4, 2021. PMID: 34098342; PMCID: PMC8176920. <https://pubmed.ncbi.nlm.nih.gov/34098342/>; [https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964\(21\)00203-6/fulltext](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00203-6/fulltext).
41. Amy S. Nowacki, Paul Terpeluk, Steven M. Gordonmed; Necessity of COVID-19 vaccination in previously infected individuals, Nabin K. Shrestha, Patrick C. Burke, ;June 6, 2021; Rxiv 2021.06.01.21258176; doi: <https://doi.org/10.1101/2021.06.01.21258176>; <https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v3>.

42. Jung JH, Rha MS, Sa M, Choi HK, Jeon JH, Seok H, Park DW, Park SH, Jeong HW, Choi WS, Shin EC. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells. *Nat Commun.* June 30, 2021;12(1):4043. doi: 10.1038/s41467-021-24377-1. PMID: 34193870; PMCID: PMC8245549. <https://pubmed.ncbi.nlm.nih.gov/34193870/>.
43. Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:1059-1062. DOI:<http://dx.doi.org/10.15585/mmwr.mm7031e2>; <https://pubmed.ncbi.nlm.nih.gov/32616673/>.
44. Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S, Yamada S, Kinoshita H, Nojima K, Kanno T, Tobiume M, Ishijima K, Kuroda Y, Park ES, Onodera T, Matsumura T, Takano T, Terahara K, Isogawa M, Nishiyama A, Kawana-Tachikawa A, Shinkai M, Tachikawa N, Nakamura S, Okai T, Okuma K, Matano T, Fujimoto T, Maeda K, Ohnishi M, Wakita T, Suzuki T, Takahashi Y. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. *Immunity.* Epub July 2, 2021. PMID: 34246326; PMCID: PMC8249673; <https://pubmed.ncbi.nlm.nih.gov/34246326/>.
45. N Kojima, A Roshani, M Brobeck, A Baca, JD Klausner; Incidence of Severe Acute Respiratory Syndrome Coronavirus-2 infection among previously infected or vaccinated employees; July 3, 2021; medRxiv 2021.07.03.21259976; doi:<https://doi.org/10.1101/2021.07.03.21259976>; <https://www.medrxiv.org/content/10.1101/2021.07.03.21259976v2.full-text>.
46. Single cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine Suhas Sureshchandra, Sloan A. Lewis, Brianna Doratt, Allen Jankeel, Izabela Ibraim, Ilhem Messaoudi; July 14, 2021; bioRxiv 2021.07.14.452381; doi: <https://doi.org/10.1101/2021.07.14.452381>; <https://www.biorxiv.org/content/10.1101/2021.07.14.452381v1>.
47. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown KE, Hopkins S, Chand M, Ramsay M. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med.* 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub July 21, 2021. PMID: 34289274; PMCID: PMC8314739.<https://pubmed.ncbi.nlm.nih.gov/34289274/>; <https://www.nejm.org/doi/10.1056/NEJMoa2108891>.
48. Cohen KW, Linderman SL, Moodie Z, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. *Cell Rep Med.* July 23, 2021;2(7):100354.



doi:10.1016/j.xcrm.2021.100354;<https://doi.org/10.1016/j.xcrm.2021.100354>;  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253687/>.

49. Stephen J. Thomas, Edson D. Moreira Jr., Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John L. Perez, Gonzalo Pérez Marc, Fernando P. Polack, Cristiano Zerbini, Ruth Bailey, Kena A. Swanson, Xia Xu, Satrajit Roychoudhury, Kenneth Koury, Salim Bouguermouh, Warren V. Kalina, David Cooper, Robert W. Frencik Jr., Laura L. Hammitt, Özlem Türeci, Haylene Nell, Axel Schaefer, Serhat Ünal, Qi Yang, Paul Liberator, Dina B. Tresnan, Susan Mather, Philip R. Dormitzer, Uğur Şahin, William C. Gruber, Kathrin U. Jansen; Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine; C4591001 Clinical Trial Group. medRxiv; July 28, 2021; 2021.07.28.21261159; <https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1.full.pdf>.
50. Alice Cho, Frauke Muecksch, Dennis Schaefer-Babajew, Zijun Wang, Shlomo Finkin, Christian Gaebler, Victor Ramos, Melissa Cipolla, Marianna Agudelo, Eva Bednarski, Justin DaSilva, Irina Shimeliovich, Juan Dizon, Mridushi Daga, Katrina Millard, Martina Turroja, Fabian Schmidt, Fengwen Zhang, Tarek Ben Tanfous, Mila Jankovic, Thiago Y. Oliveria, Anna Gazumyan, Marina Caskey, Paul D. Bieniasz, Theodora Hatzioannou, Michel C. Nussenzweig; Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination; July 29, 2021; bioRxiv 2021.07.29.454333; doi: <https://doi.org/10.1101/2021.07.29.454333>; <https://www.biorxiv.org/content/10.1101/2021.07.29.454333v1>.
51. Arjun Puranik, Patrick J. Lenehan, Eli Silvert, Michiel J.M. Niesen, Juan Corchado-Garcia, John C. O'Horo, Abinash Virk, Melanie D. Swift, John Halamka, Andrew D. Badley, A.J. Venkatakrishnan, Venky Soundararajan; Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence; medRxiv 2021.08.06.21261707; August 6, 2021; doi: <https://doi.org/10.1101/2021.08.06.21261707>.
52. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK; Koen B. Pouwels, Emma Pritchard, Philippa C. Matthews, Nicole Stoesser, David W. Eyre, Karina-Doris Vihta, Thomas House, Jodie Hay, John I Bell, John N Newton, Jeremy Farrar, Derrick Crook, Duncan Cook, Emma Rourke, Ruth Studley, Tim Peto, Ian Diamond, A. Sarah Walker, the COVID-19 Infection Survey Team; August 19, 2021; medRxiv 2021.08.18.21262237; doi: <https://doi.org/10.1101/2021.08.18.21262237>; <https://www.medrxiv.org/content/10.1101/2021.08.18.21262237v1>.
53. Yafei Liu, Noriko Arase, Jun-ichi Kishikawa, Mika Hirose, Songling Li, Asa Tada, Sumiko Matsuoka, Akemi Arakawa, Kanako Akamatsu, Chikako Ono, Hui Jin, Kazuki Kishida, Wataru Nakai, Masako Kohyama, Atsushi Nakagawa, Yoshiaki Yamagishi, Hironori Nakagami, Atsushi Kumanogoh, Yoshiharu Matsuura, Daron M. Standley, Takayuki Kato, Masato Okada, Manabu Fujimoto, Hisashi Arase; The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines. bioRxiv

2021.08.22.457114; August 22, 2021; doi: <https://doi.org/10.1101/2021.08.22.457114>;  
<https://www.biorxiv.org/content/10.1101/2021.08.22.457114v1>.

54. Sivan Gazit, Roei Shlezinger, Galit Perez, Roni Lotan, Asaf Peretz, Amir Ben-Tov, Dani Cohen, Khitam Muhsen, Gabriel Chodick, Tal Patalon, Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections; August 24, 2021; medRxiv 2021.08.24.21262415; doi:<https://doi.org/10.1101/2021.08.24.21262415>; <https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v1>.
55. Peled Y, Ram E, Lavee J, et al. Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience [published online ahead of print, August 28, 2021]. *J Heart Lung Transplant*. 2021;doi:10.1016/j.healun.2021.08.010; <https://pubmed.ncbi.nlm.nih.gov/32979941/>.
56. Han M, Pandey D. ZMPSTE24 Regulates SARS-CoV-2 Spike Protein-enhanced Expression of Endothelial PAI-1. September 2021; *Am J Respir Cell Mol Biol*. 2021 Sep;65(3):300-308. doi: 10.1165/rcmb.2020-0544OC. PMID: 34003736.<http://dx.doi.org/10.1165/rcmb.2020-0544OC>.